Visium Asset Management

Skye Bioscience Announces $50.25 Million Private Placement Equity Financing

Retrieved on: 
Monday, January 29, 2024

Financing co-led by a leading life science investor and 5AM Ventures expected to fully fund obesity Phase 2 trial assessing nimacimab, Skye's differentiated peripheral CB1 inhibitor, in combination with a GLP-1R agonist

Key Points: 
  • Gross proceeds from the PIPE are expected to be $50.25 million, before deducting any placement agent fees and offering-related expenses.
  • The PIPE financing is expected to close on January 31, 2024, subject to the satisfaction of customary closing conditions.
  • The PIPE financing was co-led by a life sciences-focused investor and 5AM Ventures, with participation from Ally Bridge Group, Sphera Healthcare, Altium Capital, Driehaus Capital Management and other institutional investors.
  • Piper Sandler is acting as the lead placement agent and Oppenheimer & Co. is acting as a placement agent for the PIPE financing.

Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010

Retrieved on: 
Tuesday, January 23, 2024

Additionally, Outlook Therapeutics entered into securities purchase agreements with certain institutional and accredited investors for up to $172 million in gross proceeds to fund the advancement of ONS-5010.

Key Points: 
  • Additionally, Outlook Therapeutics entered into securities purchase agreements with certain institutional and accredited investors for up to $172 million in gross proceeds to fund the advancement of ONS-5010.
  • Outlook Therapeutics expects NORSE EIGHT topline results and resubmission of the ONS-5010 BLA by the end of calendar year 2024.
  • Outlook Therapeutics is working to address the open items and expects to resolve these comments prior to the expected completion of NORSE EIGHT.
  • The private placement is expected to provide up to $60 million in gross proceeds at closing, before deducting placement agent fees and offering expenses.

OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies to the MOSAIC Study

Retrieved on: 
Monday, November 6, 2023

PLEASANTON, Calif. and PARIS, Nov. 6, 2023 /PRNewswire/ -- OWKIN and 10x Genomics, Inc. (Nasdaq: TXG), announce they have entered into an agreement to add 10x Genomics spatial omics and single-cell technologies to the ambitious MOSAIC project, which has already garnered attention for its pioneering work in tumor analysis for therapeutic discovery.

Key Points: 
  • PLEASANTON, Calif. and PARIS, Nov. 6, 2023 /PRNewswire/ -- OWKIN and 10x Genomics, Inc. (Nasdaq: TXG), announce they have entered into an agreement to add 10x Genomics spatial omics and single-cell technologies to the ambitious MOSAIC project, which has already garnered attention for its pioneering work in tumor analysis for therapeutic discovery.
  • I am really excited that the MOSAIC study will use the 10x Visium and Chromium platforms to generate spatial and single-cell transcriptomics for thousands of cancer patients.
  • Jim Wilbur, Chief Commercial Officer at 10x Genomics, said, "We're thrilled to have our leading technologies take on such an important, enabling role in the MOSAIC study.
  • With the addition of 10x, the distinguished team of MOSAIC researchers will have access to world-class single cell and spatial tools.

New API Extends the Utility of ATX Visium SBB Security Adapter in Enterprise Environments

Retrieved on: 
Tuesday, October 31, 2023

ATX Networks , a global leader in broadband access and media distribution solutions, recently upgraded the Visium™ Set-Back Box (SBB), the company’s pocket-sized security adapter, with a generic Application Programming Interface (API) that enables the device to be controlled by third-party enterprise-grade management systems.

Key Points: 
  • ATX Networks , a global leader in broadband access and media distribution solutions, recently upgraded the Visium™ Set-Back Box (SBB), the company’s pocket-sized security adapter, with a generic Application Programming Interface (API) that enables the device to be controlled by third-party enterprise-grade management systems.
  • The API allows businesses with screens in public areas to control electronic equipment and audio/visual solutions from a central location.
  • The Visium SBB is a competitively priced Pro:Idiom®-compatible security adapter that brings world-class encryption and an Interactive Program Guide (IPG) to hospitality sites not equipped with commercial televisions.
  • The addition of the API extends the applicability of the Visium SBB to additional enterprise environments, specifically commercial locations where controlling televisions through a remote control is unmanageable or impractical.

CDE Lightband Plugs in ATX Visium SBB to Enhance Services to Commercial Customers

Retrieved on: 
Wednesday, September 6, 2023

In addition to customer retention and loyalty, a chief benefit of the Visium SBB is its ability to reduce maintenance costs and trouble calls at the senior facilities.

Key Points: 
  • In addition to customer retention and loyalty, a chief benefit of the Visium SBB is its ability to reduce maintenance costs and trouble calls at the senior facilities.
  • Before installation of the ATX SBB, power interruptions or other failures would require maintenance personnel to rescan residents’ televisions, a process that took about 15 minutes per television.
  • The Visium SBB’s capability to configure a channel lineup from a USB key in less than a minute makes it very efficient to deploy and maintain.
  • “Kudos to the AMT team for working so closely with CDE Lightband to solve this critical service issue and protect their commercial service business.”
    For more information about the Visium SBB or any of ATX’s media distribution solutions, please visit www.atx.com .

ATX Showcases Expanded Edge Compute Capabilities of Visium MD Platform at HITEC 2023

Retrieved on: 
Monday, June 26, 2023

The SMARTBOX® is based on ATX’s Visium MD8 platform and offers the industry’s best in-room entertainment experience.

Key Points: 
  • The SMARTBOX® is based on ATX’s Visium MD8 platform and offers the industry’s best in-room entertainment experience.
  • ATX is continuing its tradition of consolidating technology into a single multipurpose appliance through the edge compute capabilities of its Visium platform, which provides localized compute power to run critical applications that currently require dedicated hardware.
  • ATX will also demonstrate edge compute functionalities of the Visium MD platform in its HITEC booth (1616).
  • ATX will showcase an MD8 hosting an instance of the Visium Manager element management system, incoming streaming media and a media player/origination server on the platform’s Edge Compute Blade.

10x Genomics Launches Visium CytAssist Gene and Protein Expression Assay

Retrieved on: 
Wednesday, May 24, 2023

PLEASANTON, Calif., May 24, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of a new Visium CytAssist Gene and Protein Expression product to expand the breadth of the Visium CytAssist spatial analysis capabilities.

Key Points: 
  • Combining tissue profiling with whole transcriptome spatial analysis and high-plex protein co-detection enables a deeper, more holistic understanding of tissue organization
    PLEASANTON, Calif., May 24, 2023 /PRNewswire/ -- 10x Genomics , Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of a new Visium CytAssist Gene and Protein Expression product to expand the breadth of the Visium CytAssist spatial analysis capabilities.
  • "This launch complements our focus on multiomic analysis and broader protein capabilities on all three of our leading platforms, including single cell and in situ analysis."
  • Visium CytAssist Gene and Protein Expression enables researchers to simultaneously produce highly multiplexed protein and whole transcriptome RNA data mapped together from the same formalin-fixed, paraffin-embedded (FFPE) tissue section at high spatial resolution.
  • "We are excited to leverage the CytAssist Gene and Protein Expression solution to generate more complete assessments of protein, RNA, and morphology together on each and every tissue section," said Dr. David Gate, Assistant Professor of Neurology at Northwestern University.

Vallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock Split

Retrieved on: 
Thursday, April 20, 2023

PHILADELPHIA, PA, April 20, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) (“Vallon” or the “Company”) today announced that its stockholders have approved Proposals 1, 2, 4 and 5, related to the previously announced proposed merger with GRI Bio, Inc., a privately held biotechnology company (“GRI Bio” or “GRI”), at a special meeting of stockholders held on April 20, 2023 (the “Special Meeting”). Accordingly, at the effective time of the merger, each share of GRI’s common stock, will be automatically converted into the right to receive a number of shares of Vallon’s common stock equal to the exchange ratio, as calculated pursuant to the merger agreement. Based on a closing price of Vallon’s common stock of $0.46 per share on April 20, 2023, the exchange ratio is 0.0374.At the Special Meeting, Vallon’s stockholders also approved a reverse stock split of shares of Vallon’s common stock at a ratio anywhere in the range of not less than 1 new share for every 15 shares and not greater than 1 new share for every 40 shares outstanding (the “Reverse Split”). Vallon’s board of directors has set the Reverse Split ratio at 1-for-30, which will result in every 30 shares of Vallon common stock being converted into one share of Vallon common stock.

Key Points: 
  • Accordingly, at the effective time of the merger, each share of GRI’s common stock, will be automatically converted into the right to receive a number of shares of Vallon’s common stock equal to the exchange ratio, as calculated pursuant to the merger agreement.
  • Based on a closing price of Vallon’s common stock of $0.46 per share on April 20, 2023, the exchange ratio is 0.0374.
  • Vallon’s board of directors has set the Reverse Split ratio at 1-for-30, which will result in every 30 shares of Vallon common stock being converted into one share of Vallon common stock.
  • The closing of the merger is anticipated to take place on April 21, 2023.

ROTH MKM Announces the Addition of Dylan Dupuis, Ph.D. to its Healthcare Research Team

Retrieved on: 
Monday, March 13, 2023

ROTH MKM (“Roth”), www.roth.com , a relationship-driven investment bank focused on serving emerging growth companies and their investors, today announced that Dr. Dylan Dupuis has joined the firm’s healthcare research team, as Managing Director, Senior Research Analyst covering biotechnology.

Key Points: 
  • ROTH MKM (“Roth”), www.roth.com , a relationship-driven investment bank focused on serving emerging growth companies and their investors, today announced that Dr. Dylan Dupuis has joined the firm’s healthcare research team, as Managing Director, Senior Research Analyst covering biotechnology.
  • Prior to joining ROTH MKM, Dr. Dupuis was a SMID-cap Biotech Analyst at Altium Capital, a healthcare-focused hedge fund.
  • Prior to Altium, he spent two years at SVB Leerink as VP - Equity Research, Senior Associate.
  • Jeff Martin, CFA – Co-Director of Research, commented, “ROTH MKM continues to invest in biotechnology research talent to enhance the strength of our Healthcare platform.

10x Genomics Demonstrates Breadth, Scale and Leadership at 2023 AGBT General Meeting

Retrieved on: 
Monday, February 6, 2023

At AGBT, we're excited to showcase researchers' success with the 10x toolkit and demonstrate the power of our innovation engine to expand the boundaries of scientific research."

Key Points: 
  • At AGBT, we're excited to showcase researchers' success with the 10x toolkit and demonstrate the power of our innovation engine to expand the boundaries of scientific research."
  • 10x Genomics will host a workshop at AGBT on Wednesday, February 8, at 1:10 p.m.
  • Multiomics: 10x Genomics will showcase data to simultaneously profile gene and protein expression from the same cell across multiple multiplexed samples at scale.
  • Massive scale: As the single cell leader, 10x Genomics continues to redefine large scale and ease of use for researchers worldwide.